Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

Moslehi, J. J., Salem, J.-E., Sosman, J. A., Lebrun-Vignes, B., & Johnson, D. B. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30533-6 · Cited by 942

Immune Checkpoint Inhibitor-Associated Myocarditis

Ganatra, S., & Neilan, T. G. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0130 · Cited by 303

Cardiac troponin testing in idiopathic inflammatory myopathies and systemic sclerosis-spectrum disorders: biomarkers to distinguish between primary cardiac involvement and low-grade skeletal muscle disease activity

Hughes, M., Lilleker, J. B., Herrick, A. L., & Chinoy, H. (2015) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2014-206812 · Cited by 95

Alemtuzumab for Cytolytic Induction of Immunosuppression in Heart Transplant Recipients

Cahoon, W. D., Ensor, C. R., & Shullo, M. A. (2012) · Progress in Transplantation · doi:10.7182/pit2012241 · Cited by 15

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update

Schneider, B. J., Naidoo, J., Santomasso, B., Lacchetti, C., Adkins, S., Anadkat, M. J., Atkins, M. B., Brassil, K. J., Caterino, J. M., Chau, I., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.21.01440 · Cited by 2,498

Immune-related adverse events of checkpoint inhibitors

Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,491

Management of toxicities from immunotherapy: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

Haanen, J. B. A. G., Obéid, M., Spain, L. A., Carbonnel, F., Wang, Y.-S., Robert, C., Lyon, A. R., Wick, W., Kostine, M., Peters, S., et al. (2022) · Annals of Oncology · doi:10.1016/j.annonc.2022.10.001 · Cited by 1,454

Immune-checkpoint inhibitors: long-term implications of toxicity

Johnson, D. B., Nebhan, C. A., Moslehi, J. J., & Balko, J. M. (2022) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-022-00600-w · Cited by 982

Society for immunotherapy of cancer (SITC) clinical practice guideline on immune checkpoint inhibitor-related adverse events

Brahmer, J. R., Abu-Sbeih, H., Ascierto, P. A., Brufsky, J., Cappelli, L. C., Cortazar, F. B., Gerber, D. E., Hamad, L., Hansen, E., Johnson, D. B., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002435 · Cited by 917

Management of Acute Myocarditis and Chronic Inflammatory Cardiomyopathy: An Expert Consensus Document

Ammirati, E., Frigerio, M., Adler, E. D., Basso, C., Birnie, D. H., Brambatti, M., Friedrich, M. G., Klingel, K., Lehtonen, J., Moslehi, J. J., et al. (2020) · Circulation: Heart Failure · doi:10.1161/circheartfailure.120.007405 · Cited by 811

Recognition and Initial Management of Fulminant Myocarditis: A Scientific Statement From the American Heart Association

Kociol, R. D., Cooper, L. T., Fang, J. C., Moslehi, J. J., Pang, P. S., Sabe, M. A., Shah, R. V., Sims, D. B., Thiene, G., Vardeny, O., et al. (2020) · Circulation · doi:10.1161/cir.0000000000000745 · Cited by 625

Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment

Palaskas, N., Lopez‐Mattei, J., Durand, J. B., Iliescu, C., & Deswal, A. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.013757 · Cited by 535

NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities, Version 1.2020

Thompson, J. A., Schneider, B. J., Brahmer, J. R., Andrews, S., Armand, P. A., Bhatia, S., Budde, L. E., Costa, L. J., Davies, M. J., Dunnington, D., et al. (2020) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2020.0012 · Cited by 490

Moving towards personalized treatments of immune-related adverse events

Esfahani, K., Elkrief, A., Calabrese, C., Lapointe, R., Hudson, M., Routy, B., Miller, W. H., & Calabrese, L. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-020-0352-8 · Cited by 351

Clinical Characteristics and Treatment of Immune-Related Adverse Events of Immune Checkpoint Inhibitors

Choi, J., & Lee, S. Y. (2020) · Immune Network · doi:10.4110/in.2020.20.e9 · Cited by 309

EULAR points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors

Kostine, M., Finckh, A., Bingham, C. O., Visser, K., Leipe, J., Schulze‐Koops, H., Choy, E., Benesova, K., Radstake, T. R. D. J., Cope, A. P., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2020-217139 · Cited by 307

Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines

Alexandre, J., Cautela, J., Éderhy, S., Damaj, G. L., Salem, J., Barlési, F., Farnault, L., Charbonnier, A., Mirabel, M., Champiat, S., et al. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018403 · Cited by 303

Immune checkpoint inhibitor–associated myocarditis: manifestations and mechanisms

Moslehi, J., Lichtman, A. H., Sharpe, A. H., Galluzzi, L., & Kitsis, R. N. (2021) · Journal of Clinical Investigation · doi:10.1172/jci145186 · Cited by 237

Immune Checkpoint Inhibitor–Induced Myocarditis with Myositis/Myasthenia Gravis Overlap Syndrome: A Systematic Review of Cases

Pathak, R., Katel, A., Massarelli, E., Villaflor, V. M., Sun, V. C.-Y., & Salgia, R. (2021) · The Oncologist · doi:10.1002/onco.13931 · Cited by 233

Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis

Ma, P., Liu, J., Qin, J., Lai, L., Heo, G. S., Luehmann, H., Sultan, D., Bredemeyer, A., Bajapa, G., Feng, G., et al. (2024) · Circulation · doi:10.1161/circulationaha.122.062551 · Cited by 187

Clinical Strategy for the Diagnosis and Treatment of Immune Checkpoint Inhibitor–Associated Myocarditis: A Narrative Review

Lehmann, L. H., Cautela, J., Palaskas, N., Baik, A. H., Meijers, W. C., Allenbach, Y., Alexandre, J., Rassaf, T., Müller, O. J., Aras, M., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2021.2241 · Cited by 178

Immune-related adverse events in various organs caused by immune checkpoint inhibitors

Okiyama, N., & Tanaka, R. (2022) · Allergology International · doi:10.1016/j.alit.2022.01.001 · Cited by 170

Update on acute myocarditis

Ammirati, E., Veronese, G., Bottiroli, M., Wang, D. W., Cipriani, M., Garascia, A., Pedrotti, P., ADLER, E. D., & Frigerio, M. (2020) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2020.05.008 · Cited by 153

Cardiotoxicity of Immune Checkpoint Inhibitors

Patel, R. P., Parikh, R. B., Gunturu, K. S., Tariq, R. Z., Dani, S. S., Ganatra, S., & Nohria, A. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01070-6 · Cited by 154

The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity

Zhang, L., Reynolds, K. L., Lyon, A. R., Palaskas, N. L., & Neilan, T. G. (2021) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.11.012 · Cited by 147

Inflammatory Myositis in Cancer Patients Receiving Immune Checkpoint Inhibitors

Aldrich, J. D., Pundole, X., Tummala, S., Palaskas, N. L., Andersen, C. R., Shoukier, M., Abdel‐Wahab, N., Deswal, A. M., & Suarez-Almazor, M. E. (2020) · Arthritis & Rheumatology · doi:10.1002/art.41604 · Cited by 135

Holistic Approach to Immune Checkpoint Inhibitor-Related Adverse Events

Poto, R., Troiani, T., Criscuolo, G., Marone, G., Ciardiello, F., Tocchetti, C. G., & Varricchi, G. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.804597 · Cited by 135

Cardiotoxicity from immune checkpoint inhibitors

Michel, L., Rassaf, T., & Totzeck, M. (2019) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2019.100420 · Cited by 128

Autoimmune complications of immunotherapy: pathophysiology and management

Chan, K. K., & Bass, A. R. (2020) · BMJ · doi:10.1136/bmj.m736 · Cited by 130

Immune checkpoint inhibitor toxicities: systems-based approaches to improve patient care and research

Johnson, D. B., Reynolds, K. L., Sullivan, R. J., Balko, J. M., Patrinely, J. R., Cappelli, L. C., Naidoo, J., & Moslehi, J. J. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30107-8 · Cited by 118

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review

Shalata, W., Abu-Salman, A., Steckbeck, R., Jacob, B. M., Massalha, I., & Yakobson, A. (2021) · Cancers · doi:10.3390/cancers13205218 · Cited by 109

Exosomes derived from umbilical cord mesenchymal stem cells alleviate viral myocarditis through activating AMPK/mTOR‐mediated autophagy flux pathway

Gu, X., Li, Y., Chen, K., Wang, X., Wang, Z., Lian, H., Lin, Y., Rong, X., Chu, M., Lin, J., et al. (2020) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.15378 · Cited by 105

Immune Checkpoint Inhibitor-Associated Cardiotoxicity: Current Understanding on Its Mechanism, Diagnosis and Management

Zhou, Y., Zhu, Y., Wang, M., Xie, Y., Chen, C.-Y., Zhang, T., Xia, F., Ding, Z., & Liu, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01350 · Cited by 102

Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis

Cautela, J., Zeriouh, S., Gaubert, M., Bonello, L., Laine, M., Peyrol, M., Paganelli, F. F., Lalevée, N., Barlési, F., & Thuny, F. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001887 · Cited by 100

Clinical Pharmacology and Interplay of Immune Checkpoint Agents: A Yin-Yang Balance

Géraud, A., Gougis, P., Vozy, A., Anquetil, C., Allenbach, Y., Romano, E., Funck‐Brentano, E., Moslehi, J. J., Johnson, D. B., & Salem, J. (2020) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-022820-093805 · Cited by 97

Immune-checkpoint inhibitor-mediated myocarditis: CTLA4, PD1 and LAG3 in the heart

Munir, A. Z., Gutierrez, A., Qin, J., Lichtman, A. H., & Moslehi, J. J. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00715-5 · Cited by 97

Adverse events induced by immune checkpoint inhibitors

Perdigoto, A. L., Kluger, H. M., & Herold, K. C. (2021) · Current Opinion in Immunology · doi:10.1016/j.coi.2021.02.002 · Cited by 79

Tocilizumab for refractory severe immune checkpoint inhibitor-associated myocarditis

Doms, J., Prior, J. O., Peters, S., & Obéid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.05.005 · Cited by 76

Corticosteroid-resistant immune-related adverse events: a systematic review

Daetwyler, E., Wallrabenstein, T., König, D., Cappelli, L. C., Naidoo, J., Zippelius, A., & Laubli, H. P. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007409 · Cited by 84

Immune Checkpoint Inhibitors and Cardiac Toxicity in Patients Treated for Non-Small Lung Cancer: A Review

Sławiński, G., Wrona, A., Dąbrowska-Kugacka, A., Raczak, G., & Lewicka, E. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21197195 · Cited by 76

Myocarditis, Myositis, and Myasthenia Gravis Overlap Syndrome Associated with Immune Checkpoint Inhibitors: A Systematic Review

Lipe, D. N., Qdaisat, A. Z., Krishnamani, P. P., Nguyen, T. D., Chaftari, P. S., Messiri, N. E., Srinivasan, A., Galvis-Carvajal, E., Reyes‐Gibby, C. C., & Wattana, M. K. (2024) · Diagnostics · doi:10.3390/diagnostics14161794 · Cited by 75

Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models

Quagliariello, V., Passariello, M., Rea, D., Barbieri, A., Iovine, M., Bonelli, A., Caronna, A., Botti, G., Lorenzo, C. D., & Maurea, N. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10040179 · Cited by 68

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors

Pirozzi, F., Poto, R., Aran, L., Cuomo, A., Galdiero, M. R., Spadaro, G., Abete, P., Bonaduce, D., Marone, G., Tocchetti, C. G., et al. (2021) · Current Oncology Reports · doi:10.1007/s11912-020-01002-w · Cited by 66

Immune Checkpoint Inhibitors-Related Myocarditis: A Review of Reported Clinical Cases

Zotova, L. (2023) · Diagnostics · doi:10.3390/diagnostics13071243 · Cited by 64

Case Series of Steroid-Resistant Immune Checkpoint Inhibitor Associated Myocarditis: A Comparative Analysis of Corticosteroid and Tofacitinib Treatment

Wang, C., Lin, J., Wang, Y., Hsi, D. H., Chen, J., Liu, T., Zhou, Y., Ren, Z., Zeng, Z., Cheng, L., et al. (2021) · Frontiers in Pharmacology · doi:10.3389/fphar.2021.770631 · Cited by 67

Myositis-myasthenia gravis overlap syndrome complicated with myasthenia crisis and myocarditis associated with anti-programmed cell death-1 (sintilimab) therapy for lung adenocarcinoma

Xing, Q., Zhang, Z., Lin, Q., Shen, L., Wang, P., Zhang, S., Fan, M., & Zhu, B. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.01.79 · Cited by 62

Cardiac Toxicity Associated with Immune Checkpoint Inhibitors: A Systematic Review

Cozma, A., Sporiș, N.-D., Lazăr, A.-L., Buruiană, A., Ganea, A.-M., Mălinescu, T.-V., Berechet, B. M., Fodor, A., Sitar-Tăut, A., Vlad, C. V., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231810948 · Cited by 61

Cardiotoxicity of Contemporary Anticancer Immunotherapy

Dalbo, N., Patel, R. P., Parikh, R. B., Shah, S. P., Guha, A., Dani, S. S., & Ganatra, S. (2020) · Current Treatment Options in Cardiovascular Medicine · doi:10.1007/s11936-020-00867-1 · Cited by 60

Immunomodulating Therapies in Acute Myocarditis and Recurrent/Acute Pericarditis

Ammirati, E., Bizzi, E., Veronese, G., Groh, M., Heyning, C. M. V. D., Lehtonen, J. Y. A., de Chambrun, M. P., Cereda, A. F., Picchi, C., Trotta, L., et al. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.838564 · Cited by 61

Paraneoplastic Neurological Syndromes and Beyond Emerging With the Introduction of Immune Checkpoint Inhibitor Cancer Immunotherapy

Valencia-Sánchez, C., & Ζεκερίδου, Α. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.642800 · Cited by 58

PD-1/PDL-1 Inhibitors and Cardiotoxicity; Molecular, Etiological and Management Outlines

Safi, M., Ahmed, H., Al‐Azab, M., Xia, Y., Shan, X., Alradhi, M., Al-Danakh, A., Shopit, A., & Liu, J. (2020) · Journal of Advanced Research · doi:10.1016/j.jare.2020.09.006 · Cited by 57

Management of Cardiac Toxicity Induced by Chemotherapy

Trapani, D., Zagami, P., Nicolò, E., Pravettoni, G., & Curigliano, G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092885 · Cited by 57

Pathophysiology, diagnosis and management of cardiac toxicity induced by immune checkpoint inhibitors and BRAF and MEK inhibitors

Arangalage, D., Degrauwe, N., Michielin, O. A., Monney, P. A., & Özdemir, B. C. (2021) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2021.102282 · Cited by 56

Immune checkpoint inhibitors associated cardiovascular immune-related adverse events

Jo, W., Won, T., Daoud, A., & Čiháková, D. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1340373 · Cited by 55

Peripheral nervous system immune-related adverse events due to checkpoint inhibition

O’Hare, M., & Guidon, A. C. (2024) · Nature Reviews Neurology · doi:10.1038/s41582-024-01001-6 · Cited by 56

Cardiovascular toxicity of immune therapies for cancer

Palaskas, N. L., Ali, H.-J., Koutroumpakis, E., Ganatra, S., & Deswal, A. M. (2024) · BMJ · doi:10.1136/bmj-2023-075859 · Cited by 61

Autoimmune Myocarditis, Old Dogs and New Tricks.

Won, T., Song, E. J., Kalinoski, H. M., Moslehi, J. J., & Čiháková, D. (2024) · Circulation Research · doi:10.1161/circresaha.124.323816 · Cited by 51

Potential therapies for immune-related adverse events associated with immune checkpoint inhibition: from monoclonal antibodies to kinase inhibition

Berg, M. H., Rincon, S. V. D., & Miller, W. H. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003551 · Cited by 53

Diretriz de Miocardites da Sociedade Brasileira de Cardiologia – 2022

Montera, M. W., Marcondes‐Braga, F. G., Simões, M. V., Moura, L. Z., Fernandes, F., Mangini, S., de Oliveira, A. C., de Souza, A. L. A. D. A. G., Ianni, B. M., Rochitte, C. E., et al. (2022) · Arquivos Brasileiros de Cardiologia · doi:10.36660/abc.20220412 · Cited by 50

Novel Therapeutic Approach Targeting CXCR3 to Treat Immunotherapy Myocarditis

Huang, Y. V., Sun, Y., Chou, H., Wagner, N., Vitale, M. R., Bayer, A. L., Xu, B., Lee, D. C., Lin, Z., Branche, C., et al. (2025) · Circulation Research · doi:10.1161/circresaha.124.325652 · Cited by 51

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians

Raschi, E., Rossi, S., Giglio, A. D., Fusaroli, M., Burgazzi, F., Rinaldi, R., & Potena, L. (2023) · Drug Safety · doi:10.1007/s40264-023-01320-5 · Cited by 48

Immune-related pulmonary toxicities of checkpoint inhibitors in non-small cell lung cancer: Diagnosis, mechanism, and treatment strategies

Guo, X., Chen, S., Wang, X., & Liu, X. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1138483 · Cited by 46

Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases

Matzen, E., Bartels, L. E., Løgstrup, B. B., Madsen, S. H., Stilling, C., & Donskov, F. N. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00114-x · Cited by 47

Mechanisms and clinical manifestations of cardiovascular toxicities associated with immune checkpoint inhibitors

Baik, A. H., Tsai, K. K., Oh, D. Y., & Aras, M. A. (2021) · Clinical Science · doi:10.1042/cs20200331 · Cited by 42

Targeted degradation of immune checkpoint proteins: emerging strategies for cancer immunotherapy

Xu, J., Brosseau, J., & Shi, H. (2020) · Oncogene · doi:10.1038/s41388-020-01491-w · Cited by 41

Steroid-Refractory Immune-Related Adverse Events Induced by Checkpoint Inhibitors

Tomsitz, D., Ruf, T., Zierold, S., French, L. E., & Heinzerling, L. M. (2023) · Cancers · doi:10.3390/cancers15092538 · Cited by 40

Plasma Exchange for Immune Checkpoint Inhibitor–Induced Myocarditis

Yogasundaram, H., Alhumaid, W., Chen, J. W., Church, M., Alhulaimi, N., Kimber, S., Paterson, D. I., & Senaratne, J. M. (2020) · CJC Open · doi:10.1016/j.cjco.2020.11.004 · Cited by 40

Immune checkpoint inhibitors for solid organ transplant recipients: clinical updates

Kawashima, S., Joachim, K., Abdelrahim, M., Abudayyeh, A., Jhaveri, K. D., & Murakami, N. (2022) · Korean Journal of Transplantation · doi:10.4285/kjt.22.0013 · Cited by 39

Therapeutic strategies for virus-negative myocarditis: a comprehensive review

Luca, G. D. D., Campochiaro, C., Sartorelli, S., Peretto, G., & Dagna, L. (2020) · European Journal of Internal Medicine · doi:10.1016/j.ejim.2020.04.050 · Cited by 38

Immune Checkpoint Inhibitor-Associated Myocarditis With Persistent Troponin Elevation Despite Abatacept and Prolonged Immunosuppression

Liu, S., Chan, J., Brinc, D., Gandhi, S., Izenberg, A., Delgado, D., Abdel-Qadir, H. M., Wintersperger, B. J., & Thavendiranathan, P. (2020) · JACC CardioOncology · doi:10.1016/j.jaccao.2020.10.013 · Cited by 37

Cancer Therapy-Related Cardiovascular Complications in Clinical Practice: Current Perspectives

Bohdan, M., Kowalczys, A., Mickiewicz, A., Gruchała, M., & Lewicka, E. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081647 · Cited by 39

Immune Checkpoint Inhibitors in Breast Cancer: A Narrative Review

Filho, P. N., Albuquerque, C., Capella, M. P., & Debiasi, M. (2023) · Oncology and Therapy · doi:10.1007/s40487-023-00224-9 · Cited by 39

Management perspectives from the 2019 Wuhan international workshop on fulminant myocarditis

Veronese, G., Ammirati, E., Chen, C., Klingel, K., Suzuki, M., Okumura, T., Maisch, B., Zuo, H., Ni, L., Jiang, J., et al. (2020) · International Journal of Cardiology · doi:10.1016/j.ijcard.2020.10.063 · Cited by 34

Treatment of corticosteroid refractory immune checkpoint inhibitor myocarditis with Infliximab: a case series

Zhang, R. S., Padegimas, A., Murphy, K. M., Evans, P. T., Peters, C. J., Domenico, C. M., Vidula, M. K., Mather, P. J., Cevasco, M., Cohen, R. B., et al. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00095-x · Cited by 35

Chinese Society of Cardiology guidelines on the diagnosis and treatment of adult fulminant myocarditis

Jiang, J., Shu, H., Wang, D. W., Hui, R., Li, C., Ran, X., Wang, H., Zhang, J., Nie, S., Cui, G., et al. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2421-0 · Cited by 33

TNF-α Inhibitors and Other Biologic Agents for the Treatment of Immune Checkpoint Inhibitor-Induced Myocarditis

Liu, X., Wu, W., Fang, L., Liu, Y., & Chen, W. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.922782 · Cited by 33

Treatment strategies and safety of rechallenge in the setting of immune checkpoint inhibitors-related myositis: a national multicentre study

Weill, A., Delyon, J., Descamps, V., Deschamps, L., Dinulescu, M., Dupuy, A., Celérier, P., Nardin, C., Aubin, F., Corre, Y. L., et al. (2021) · Rheumatology · doi:10.1093/rheumatology/keab249 · Cited by 31

Deleterious Role of Th9 Cells in Pulmonary Fibrosis

Deng, K., Yang, X. S., Luo, Q., She, Y. X., Yu, Q. Y., & Tang, X. X. (2021) · Cells · doi:10.3390/cells10113209 · Cited by 33

Cardiotoxicity Induced by Immune Checkpoint Inhibitors: What a Cardio-Oncology Team Should Know and Do

Zito, C., Manganaro, R., Ciappina, G., Spagnolo, C. C., Racanelli, V., Santarpía, M., Silvestris, N., & Carerj, S. (2022) · Cancers · doi:10.3390/cancers14215403 · Cited by 32

Current Treatment and Immunomodulation Strategies in Acute Myocarditis

Ferone, E., Segev, A., Tempo, E., Gentile, P., Elsanhoury, A., Baggio, C., Artico, J., Bhatti, P., Scott, P. A., Bobbio, E., et al. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001542 · Cited by 29

Immune Myocarditis Overlapping With Myasthenia Gravis Due to Anti-PD-1 Treatment for a Chordoma Patient: A Case Report and Literature Review

Liang, S., Yang, J., Lin, Y. P., Li, T., Zhao, W., Zhao, J., & Dong, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.682262 · Cited by 29

Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies

Ronen, D., Bsoul, A., Lotem, M., Abedat, S., Yarkoni, M., Amir, O., & Asleh, R. (2022) · Vaccines · doi:10.3390/vaccines10040540 · Cited by 29

PD-1/PD-L1 Inhibitor-Associated Myocarditis: Epidemiology, Characteristics, Diagnosis, Treatment, and Potential Mechanism

Dong, H., Qi, Y., Kong, X., Wang, Z., Fang, Y., & Wang, J. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.835510 · Cited by 28

Cardiotoxicity in cancer immune-checkpoint therapy: Mechanisms, clinical evidence, and management strategies

Sun, J.-Y., Qu, Q., Lou, Y.-X., Yang, H., Sun, G.-Z., Sun, W., & Kong, X. (2021) · International Journal of Cardiology · doi:10.1016/j.ijcard.2021.09.041 · Cited by 27

Mediators and mechanisms of immune checkpoint inhibitor‐associated myocarditis: Insights from mouse and human

Gong, J., Neilan, T. G., & Zlotoff, D. A. (2023) · Immunological Reviews · doi:10.1111/imr.13240 · Cited by 28

Diagnosis, risk stratification and management of myocarditis

Müller, M., Cooper, L. T., & Heidecker, B. (2021) · Heart · doi:10.1136/heartjnl-2021-319027 · Cited by 26

Immune checkpoint inhibitor–associated myocarditis: a systematic analysis of case reports

Wang, C., Zhao, G., Zhang, Z., Yang, L., Liu, S., Li, G., Wang, H., Huang, J., Wang, S., & Li, N. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1275254 · Cited by 26

Tocilizumab for Fulminant Programmed Death 1 Inhibitor–Associated Myocarditis

Wang, H., Tian, R., Gao, P., Wang, Q., & Zhang, L. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.080 · Cited by 25

Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit

Deharo, F., Carvelli, J., Cautela, J., Garcia, M., Sarles, C., de Paula, A. M., Bourenne, J., Gainnier, M., & Bichon, A. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11195611 · Cited by 27

Immune-Checkpoint Inhibitor-Induced Fulminant Myocarditis and Cardiogenic Shock

Zadok, O. I. B., Ben‐Avraham, B., Nohria, A., Orvin, K., Nassar, M., Iakobishvili, Z., Neiman, V., Goldvaser, H., Kornowski, R., & Gal, T. B. (2019) · JACC CardioOncology · doi:10.1016/j.jaccao.2019.07.004 · Cited by 23

Immune checkpoint inhibitor-associated cardiovascular toxicities: A review

Liu, G., Chen, T., Zhang, X., Hu, B., & Shi, H. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e25747 · Cited by 24

Anti-inflammatory pharmacotherapy in patients with cardiovascular disease

Finocchiaro, S., Mazzone, P. M., Ammirabile, N., Bordonaro, C., Cusmano, C., Cutore, L., Leo, G. D., Faro, D. C., Giacoppo, D., Greco, A., et al. (2025) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaf058 · Cited by 22

Immune Checkpoint Inhibitors and Infection: What Is the Interplay?

Papadakis, M., Karniadakis, I., Mazonakis, N., Akinosoglou, K., Tsioutis, C., & Spernovasilis, N. A. (2023) · In Vivo · doi:10.21873/invivo.13346 · Cited by 21

Cardioprotective Strategies to Prevent Cancer Treatment-Related Cardiovascular Toxicity: a Review

Upshaw, J. N. (2020) · Current Oncology Reports · doi:10.1007/s11912-020-00923-w · Cited by 22

Myocarditis associated with immune check-point inhibitors: Practical considerations in diagnosis and management

Gürdoğan, M. (2020) · The Anatolian Journal of Cardiology · doi:10.14744/anatoljcardiol.2020.79584 · Cited by 21

Camrelizumab-Related Myocarditis and Myositis With Myasthenia Gravis: A Case Report and Literature Review

Bai, J., Li, D., Yang, P., Xu, K., Wang, Y., Li, Q., Liu, J., Du, W., Zhang, F., & Feng, R. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2021.778185 · Cited by 21

Drug therapy for myocarditis induced by immune checkpoint inhibitors

Wu, Y., Xu, Y., & Xu, L. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1161243 · Cited by 20

Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system

Michel, L., Totzeck, M., Lehmann, L., & Finke, D. (2020) · Herz · doi:10.1007/s00059-020-04954-8 · Cited by 19

Mechanisms and Management of Immune Checkpoint Inhibitor-Related Cardiac Adverse Events

Kadowaki, H., Akazawa, H., Ishida, J., & Komuro, I. (2021) · JMA Journal · doi:10.31662/jmaj.2021-0001 · Cited by 19

Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review

Madanat, L., Gupta, R., Weber, P., Kumar, N., Chandra, R., Ahaneku, H. P., Bansal, Y., Anderson, J., Bilolikar, A., & Jaiyesimi, I. A. (2022) · Current Cardiology Reviews · doi:10.2174/1573403x18666220531094800 · Cited by 20

An Emergent Form of Cardiotoxicity: Acute Myocarditis Induced by Immune Checkpoint Inhibitors

Esposito, R., Fedele, T., Orefice, S., Cuomo, V., Prastaro, M., Canonico, M. E., Ilardi, F., Stefano, F. D., Fiorillo, L., Santoro, C., et al. (2021) · Biomolecules · doi:10.3390/biom11060785 · Cited by 18

Cardiac Toxicities Associated with Immune Checkpoints Inhibitors: Mechanisms, Manifestations and Management

Zarifa, A., Kim, J. W., Lopez‐Mattei, J., Palaskas, N. L., Iliescu, C., & Kim, P. Y. (2021) · Korean Circulation Journal · doi:10.4070/kcj.2021.0089 · Cited by 17

Analysis of clinical characteristics of mesalazine-induced cardiotoxicity

Chen, J., Duan, T., Fang, W., Liu, S., & Wang, C. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.970597 · Cited by 17

Treatment of Immune Checkpoint Inhibitor-associated Myocarditis

Heemelaar, J. C., Louisa, M., & Neilan, T. G. (2023) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001456 · Cited by 19

Tocilizumab for Fulminant Programmed Death 1 Inhibitor–Associated Myocarditis

Wang, H., Tian, R., Gao, P., Wang, Q., & Zhang, L. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.09.080 · Cited by 25

Avelumab-Induced Myocarditis: A Case of Steroid-Refractory Immune Checkpoint Inhibitor Cardiotoxicity

Nirthanakumaran, D., Chiswell, K., Moussad, A., Gurney, H., & Brown, M. R. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2026.07.381

Case Analysis of Immune-Related Myocarditis Induced by PD-1 Inhibitors

史, 婉. (2022) · Advances in Clinical Medicine · doi:10.12677/acm.2022.123280

Plasma exchange plus glucocorticoids in the treatment of immune checkpoint inhibitor‐induced myocarditis: A case series and review

Ke, G., Chen, P., Luo, J., Huang, J., Shang, Y., Huang, Y., Fu, N., Peng, H., Li, Y., Wang, B., et al. (2023) · Clinical Cardiology · doi:10.1002/clc.24149 · Cited by 10

Use of Infliximab in the Treatment of Immune Checkpoint Inhibitors-Related Myocarditis: A Systematic Review of Case Reports

PHING, K. C., Gnanasan, S., & Tangiisuran, B. (2024) · Malaysian Journal of Pharmaceutical Sciences · doi:10.21315/mjps2024.22.1.7